Fisher B, ... Oishi RH
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001
Reviewers: John Han-Chih Chang, MD
Source: Lancet 1999 Jun 12; Volume 353: pages 1993 - 2000
The focus of this NSABP trial was to evaluate if the addition of tamoxifen could improve on the local recurrence rates in patients receiving lumpectomy and RT. Tamoxifen is a nonsteroidal anti-estrogen that binds the estrogen receptors on cells and competitively inhibits estrogen binding. This causes a blockade of the cell cycle transit at G1, possibly leading to apoptosis. The beneficial effects of tamoxifen have been found to be preservation of bone mineral density in postmenopausal women and improvement of the lipid profile. The possible toxicities are deep venous thrombosis (1.7% tam versus 0.4% placebo), ocular degeneration and ovarian cysts. Endometrial cancer incidence is increased by 3 to 8 times the normal frequency. In a prior NSABP and other prospective studies for invasive breast cancer patients, there was improvement in outcome with the addition of tamoxifen in women who were estrogen receptor positive.
This current trial enrolled DCIS patients who could have fairly extensive tumors and even positive margins. Tamoxifen appeared to significantly lower total breast cancer events as indicated above. The breakdown is as indicated in the table below:
All Breast Cancer
The results seem consistent with prior trials and retrospective data in regards to the control arm of lumpectomy and RT without tamoxifen. The reduction in invasive recurrences along with the contralateral non-invasive recurrence rates are the major factors in tamoxifen's benefit. The rate of endometrial cancer wasincreased but not significantly. The benefit seems to outweigh the increased risk. There was an increase in the grade 1 - 2 toxicities (hot flashes, menstrual disorders, fluid retention and vaginal discharge), but not in the overall severe (grade 3 or 4) complications (5.4% in the tamoxifen arm versus 4.3% in placebo arm). There was increased deep venous thrombosis incidence (1% in the tamoxifen arm versus 0.2% in the placebo arm). Overall survival at 5 years was 97% for all patients and was not significantly different in the two arms.
Overall, this trial has seemed to answer the question of whether tamoxifen is beneficial in prevention of recurrence. However, since most recurrences can occur in the first 6 years (and even further out), whether tamoxifen truly decreases recurrences may not be answered until a few years from now. What the article did a poor job addressing was whether there was a subgroup of patients that would not require tamoxifen. It states that even patients with comedo necrosis and positive margins benefited, but did not fully discuss whether they went through enough analysis to determine what patients may not benefit -- since tamoxifen is not an altogether benign drug.
In conclusion, tamoxifen has been proven to be of benefit in chemoprevention and invasive breast cancer (both pre- and postmenopausal). It now has found a new avenue for its application, but oncologists should not to be too caviler as survival is not improved with tamoxifen. The same could be stated about RT added to lumpectomy, albeit the amount of benefit is greater. Should we subject patients to additional risks for local control and breast conservation benefits only? Careful counseling must be instituted in each individual patient.